Anti-CD19 chimeric antigen receptor T cell therapy - Shanghai GenechemAlternative Names: Anti-CD19 CAR-T cells - Shanghai Genechem
Latest Information Update: 13 May 2016
At a glance
- Originator Shanghai Genechem
- Class Antineoplastics; CAR-T cell therapies
- Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Leukaemia
Most Recent Events
- 01 Jan 2016 Phase-I/II clinical trials in Leukaemia (Late-stage disease, Second-line therapy or greater) in China (Infusion) (NCT02672501)